for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bristol-Myers Squibb Co

BMY

Latest Trade

59.70USD

Change

0.23(+0.39%)

Volume

6,804,034

Today's Range

59.41

 - 

60.38

52 Week Range

44.90

 - 

68.34

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
59.47
Open
59.95
Volume
6,804,034
3M AVG Volume
302.15
Today's High
60.38
Today's Low
59.41
52 Week High
68.34
52 Week Low
44.90
Shares Out (MIL)
2,263.00
Market Cap (MIL)
133,725.00
Forward P/E
9.45
Dividend (Yield %)
3.05

Next Event

Q2 2020 Bristol-Myers Squibb Co Earnings Release

Latest Developments

More

Bristol Myers Squibb Board Elects Two New Independent Directors

Bristol Myers Squibb And Bluebird Bio Announce Submission Of Biologics License Application (BLA) To FDA For Idecabtagene Vicleucel

Dragonfly Therapeutics Announces Research Collaboration With Bristol Myers Squibb

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Bristol-Myers Squibb Co

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company's products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. The Company’s subsidiary is Celgene Corp.

Industry

Biotechnology & Drugs

Contact Info

430 E 29th St Fl 14

NEW YORK, NY

10016-8367

United States

+1.212.5464000

https://www.bms.com/

Executive Leadership

Giovanni Caforio

Chairman of the Board, Chief Executive Officer

David V. Elkins

Executive Vice President and Chief Financial Officer Member of the Leadership Team

Ann Powell Judge

Chief Human Resource Officer, Senior Vice President Member of the Leadership Team

Sandra Leung

Executive Vice President, General Counsel

John E. Elicker

Executive Vice President of Investor Relations

Key Stats

1.94 mean rating - 17 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

20.8K

2018

22.6K

2019

26.1K

2020(E)

41.9K
EPS (USD)

2017

3.010

2018

3.980

2019

4.690

2020(E)

6.199
Price To Earnings (TTM)
73.05
Price To Sales (TTM)
4.31
Price To Book (MRQ)
2.68
Price To Cash Flow (TTM)
26.33
Total Debt To Equity (MRQ)
93.58
LT Debt To Equity (MRQ)
85.84
Return on Investment (TTM)
1.44
Return on Equity (TTM)
1.19

Latest News

Latest News

BRIEF-Dragonfly Therapeutics Announces Research Collaboration With Bristol Myers Squibb

* DRAGONFLY THERAPEUTICS ANNOUNCES NEW RESEARCH COLLABORATION WITH BRISTOL MYERS SQUIBB TO DEVELOP NOVEL THERAPEUTIC CANDIDATES FOR MULTIPLE SCLEROSIS AND NEURO-INFLAMMATION TARGET

BRIEF-Agios And Royalty Pharma Announce $255 Mln Purchase Agreement For IDHIFA Royalty

* AGIOS AND ROYALTY PHARMA ANNOUNCE $255 MILLION PURCHASE AGREEMENT FOR IDHIFA® ROYALTY

BRIEF-Bristol-Myers Squibb Says Declared Quarterly Dividend Of Forty-Five Cents Per Share On $.10 Par Value Common Stock Of Corp

* BRISTOL-MYERS SQUIBB CO - DECLARED A QUARTERLY DIVIDEND OF FORTY-FIVE CENTS PER SHARE ON $.10 PAR VALUE COMMON STOCK OF CORPORATION Source text for Eikon: Further company coverage:

BRIEF-Jounce Therapeutics Regains Worldwide Rights To JTX-8064 From Bristol Myers Squibb

* JOUNCE THERAPEUTICS REGAINS WORLDWIDE RIGHTS TO JTX-8064 FROM BRISTOL MYERS SQUIBB

BRIEF-Bristol-Myers - New Data Reinforce Durable Clinical Responses Of Orencia In Early Rheumatoid Arthritis

* NEW DATA REINFORCE IMPROVED AND DURABLE CLINICAL RESPONSES OF ORENCIA IN MODERATE-TO-SEVERE EARLY RHEUMATOID ARTHRITIS PATIENTS WITH AUTOANTIBODIES LINKED TO MORE SEVERE DISEASE

BRIEF-Bristol Myers Announces Results From Phase 3 Zeposia Study In Ulcerative Colitis

* BRISTOL MYERS - ANNOUNCES TOPLINE RESULTS FROM PHASE 3 TRUE NORTH TRIAL EVALUATING ZEPOSIA IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Bristol Myers' treatment succeeds in late-stage bowel disease study

U.S. drugmaker Bristol Myers Squibb Co said on Tuesday its treatment Zeposia, which it gained through its $74 billion buyout of Celgene last year, met the main goals of a late-stage study testing it in patients with an inflammatory bowel disease.

BRIEF-Bristol Myers Squibb Reports Commercial Launch Of Zeposia For Multiple Sclerosis

* BRISTOL MYERS SQUIBB ANNOUNCES COMMERCIAL LAUNCH AND AVAILABILITY OF ZEPOSIA® (OZANIMOD), A NEW ORAL TREATMENT FOR RELAPSING FORMS OF MULTIPLE SCLEROSIS Source text for Eikon: Further company coverage:

BRIEF-U.S. FDA Approves Opdivo, Yervoy With Limited Chemotherapy As First-Line Treatment Of Metastatic Or Recurrent Non-Small Cell Lung Cancer

* U.S. FOOD AND DRUG ADMINISTRATION APPROVES OPDIVO® (NIVOLUMAB) + YERVOY® (IPILIMUMAB) COMBINED WITH LIMITED CHEMOTHERAPY AS FIRST-LINE TREATMENT OF METASTATIC OR RECURRENT NON-SMALL CELL LUNG CANCER

BRIEF-Repare Therapeutics Enters Into Research Collaboration With Bristol Myers Squibb

* REPARE THERAPEUTICS - ENTERED INTO EXCLUSIVE, WORLDWIDE RESEARCH COLLABORATION WITH BRISTOL MYERS SQUIBB

BRIEF-European Medicines Agency Validates Bristol Myers Squibb's Applications For Idecabtagene Vicleucel And Cc-486

* EUROPEAN MEDICINES AGENCY VALIDATES BRISTOL MYERS SQUIBB’S APPLICATIONS FOR IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) AND CC-486 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Bristol-Myers Squibb Announced Presentation Of Data Across Its Hematology Portfolio At EHA Annual Congress

* BRISTOL-MYERS SQUIBB CO - ANNOUNCED PRESENTATION OF DATA ACROSS ITS HEMATOLOGY PORTFOLIO AT EHA ANNUAL CONGRESS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Bristol-Myers Spokesperson Says Estimated Cost Of Opdivo + Yervoy Is $104,233

* BRISTOL-MYERS SPOKESPERSON SAYS BASED ON A MEDIAN OF NINE DOSES OF OPDIVO AND THREE OF YERVOY, ESTIMATED COST OF OPDIVO + YERVOY IS $104,233

FDA approves Bristol-Myers combo therapy for lung cancer

The U.S. Food and Drug Administration on Friday approved Bristol Myers Squibb Co's combination therapy for previously untreated patients with a form of lung cancer, a much-needed boost as the company battles the dominance of Merck's Keytruda.

U.S. FDA approves Bristol Myers' combo therapy for lung cancer

The U.S. Food and Drug Administration on Friday approved Bristol Myers Squibb Co's therapy for previously untreated patients with a form of lung cancer, a much-needed boost as the company battles the dominance of Merck's Keytruda.

BRIEF-U.S. FDA Approves Bristol Myers' Pomalyst For AIDS-Related And HIV-Negative Kaposi Sarcoma

* U.S. FOOD AND DRUG ADMINISTRATION APPROVES BRISTOL MYERS SQUIBB’S POMALYST® (POMALIDOMIDE) FOR AIDS-RELATED AND HIV-NEGATIVE KAPOSI SARCOMA

BRIEF-Bristol-Myers Says Opdivo Plus Yervoy Effective As First-Line Treatment For Non-Small Cell Lung Cancer Patients

* THREE-YEAR DATA FROM CHECKMATE -227 CONFIRM DURABLE, LONG-TERM SURVIVAL BENEFIT FOR OPDIVO (NIVOLUMAB) PLUS YERVOY (IPILIMUMAB) VERSUS. CHEMOTHERAPY IN METASTATIC FIRST-LINE NON-SMALL CELL LUNG CANCER PATIENTS WITH PD-L1 ≥1%

BRIEF-Bluebird Bio To Present Updated Positive Results From Phase 2 Karmma Study At ASCO20

* BRISTOL MYERS SQUIBB AND BLUEBIRD BIO TO PRESENT UPDATED POSITIVE RESULTS FROM PIVOTAL KARMMA STUDY OF IDE-CEL IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS AT ASCO20

Bristol Myers, bluebird to resubmit cancer therapy filing as FDA declines review

Bristol Myers Squibb Co said on Wednesday it planned to resubmit its application for an experimental multiple myeloma therapy by the end of July after the U.S. drug regulator declined to review the treatment as it sought more information.

BRIEF-Bristol Myers Squibb, Bluebird Bio Provide Regulatory Update On Ide-Cel, Bb2121 For Treatment Of Patients With Multiple Myeloma

* BRISTOL MYERS SQUIBB AND BLUEBIRD BIO PROVIDE REGULATORY UPDATE ON IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up